The Colorado Fragile X Consortium arose as a means of strengthening the growing network of Colorado-based researchers and clinicians dedicated to the study and treatment of disorders associated with the fragile X gene. Based at the University of Colorado Denver (UCD), the Consortium includes members of the UCD School of Medicine, faculty from The Children's Hospital in Denver, Colorado, and clinicians from Developmental FX, a non-profit organization providing clinical services to individuals with fragile X syndrome and other neurodevelopmental disorders. Consortium members include pediatricians, neurologists, neuropsychologists, as well as speech and occupational therapists who specialize in the diagnosis and treatment of fragile X syndrome, the fragile X premutation, and fragile X-associated tremor/ataxia syndrome (FXTAS).
In addition to working to educate health care providers and the community about fragile X syndrome and related disorders, the members of the Consortium direct or collaborate with other top researchers in the United States and internationally to conduct critical research projects that will help to clarify the nature of disorders associated with the fragile X gene. In 2001, scientists at the M.I.N.D. Institute at the University of California, Davis, and members of the Colorado Fragile X Consortium were the first to report the existence of FXTAS in carriers of the fragile X premutation. Consortium members currently are involved with research projects examining the prevalence and genetic nature of FXTAS as well as cognitive, neurological, and functional impairment in FXTAS. Information about current studies being conducted by Consortium members is available through the Consortium Research link to the left.